Vitamin D and Osteogenesis Imperfecta in Pediatrics

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 May 27

PMID 37242473

Authors

Francesco Coccia

Angelo Pietrobelli

Thomas Zoller

Alessandra Guzzo

Paolo Cavarzere

Angelo Fassio

Carl-Erik Flodmark

Davide Gatti

Franco Antoniazzi

Affiliations

Soon will be listed here.

Abstract

Osteogenesis Imperfecta (OI) is a heterogeneous group of inherited skeletal dysplasias characterized by bone fragility. The study of bone metabolism, in these disease, is problematic in terms of clinical and genetic variability. The aims of our study were to evaluate the importance of Vitamin D levels in OI bone metabolism, reviewing studies performed on this topic and providing advice reflecting our experience using vitamin D supplementation. A comprehensive review on all English-language articles was conducted in order to analyze the influence of vitamin D in OI bone metabolism in pediatric patients. Reviewing the studies, contradictory data were found on the relationship between 25OH vitamin D levels and bone parameters in OI, and in several studies the baseline levels of 25OH D were below the threshold value of 75 nmol/L. In conclusion, according to the literature and to our experience, we highlight the importance of adequate vitamin D supplementation in children with OI.

Citing Articles

The vitamin D status in a Chinese osteogenesis imperfecta population and its correlation with bone metabolic markers and bone density.

Jiang Y, Mei Y, Tian Y, Shen L, Xu S, Zhang H Front Nutr. 2024; 11:1390668.

PMID: 39161912 PMC: 11333034. DOI: 10.3389/fnut.2024.1390668.

Nutritional Behavior of Patients with Bone Diseases: A Cross-Sectional Study from Austria.

Kraus D, Medibach A, Behanova M, Kocijan A, Haschka J, Zwerina J Nutrients. 2024; 16(12).

PMID: 38931274 PMC: 11206606. DOI: 10.3390/nu16121920.

References

Edouard T, Husseini A, Glorieux F, Rauch F . Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters. J Clin Endocrinol Metab. 2012; 97(4):1243-9. DOI: 10.1210/jc.2011-3015. View

Pilz S, Trummer C, Theiler-Schwetz V, Grubler M, Verheyen N, Odler B . Critical Appraisal of Large Vitamin D Randomized Controlled Trials. Nutrients. 2022; 14(2). PMC: 8778517. DOI: 10.3390/nu14020303. View

Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G . Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010; 6:367-81. PMC: 2940745. DOI: 10.2147/tcrm.s5932. View

Maines E, Tadiotto E, Morandi G, Fedrizzi M, Gaudino R, Cavarzere P . Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study. J Pediatr Genet. 2020; 9(2):93-100. PMC: 7183406. DOI: 10.1055/s-0039-1700972. View

Chagas C, Roque J, Peters B, Lazaretti-Castro M, Araujo Martini L . Do patients with osteogenesis imperfecta need individualized nutritional support?. Nutrition. 2011; 28(2):138-42. DOI: 10.1016/j.nut.2011.04.003. View

Bian Q, McAdam L, Grynpas M, Mitchell J, Harrington J . Increased Rates of Vitamin D Insufficiency in Boys With Duchenne Muscular Dystrophy Despite Higher Vitamin D Supplementation. Glob Pediatr Health. 2019; 6:2333794X19835661. PMC: 6421611. DOI: 10.1177/2333794X19835661. View

Edouard T, Glorieux F, Rauch F . Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab. 2011; 96(10):3193-8. DOI: 10.1210/jc.2011-1480. View

Marom R, Lee Y, Grafe I, Lee B . Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J Med Genet C Semin Med Genet. 2016; 172(4):367-383. DOI: 10.1002/ajmg.c.31532. View

Idolazzi L, Fassio A, Viapiana O, Rossini M, Adami G, Bertoldo F . Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Bone. 2017; 103:144-149. DOI: 10.1016/j.bone.2017.07.004. View

10.

Marini J, Forlino A, Bachinger H, Bishop N, Byers P, De Paepe A . Osteogenesis imperfecta. Nat Rev Dis Primers. 2017; 3:17052. DOI: 10.1038/nrdp.2017.52. View

11.

Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O . Bone turnover markers in patients with osteogenesis imperfecta. Bone. 2004; 34(6):1013-6. DOI: 10.1016/j.bone.2004.02.023. View

12.

Zambrano M, Brizola E, Pinheiro B, Vanz A, Mello E, Felix T . Study of the Determinants of Vitamin D Status in Pediatric Patients With Osteogenesis Imperfecta. J Am Coll Nutr. 2015; 35(4):339-45. DOI: 10.1080/07315724.2015.1057776. View

13.

Edouard T, Glorieux F, Rauch F . Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: histomorphometric study. J Bone Miner Res. 2011; 26(9):2245-51. DOI: 10.1002/jbmr.413. View

14.

Bishop N . Bone Material Properties in Osteogenesis Imperfecta. J Bone Miner Res. 2016; 31(4):699-708. DOI: 10.1002/jbmr.2835. View

15.

de Paz I, Rosado Sierra J, Perez Blanco C, Modrono Mostoles N, Guijarro de Armas G, Navea Aguilera C . Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up. Endocrinol Diabetes Nutr (Engl Ed). 2018; 66(2):108-116. DOI: 10.1016/j.endinu.2018.05.015. View

16.

Pisani D, Cipriani C, Celli M, Zambrano A, Diacinti D, Kripa E . Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate. Bone. 2020; 143:115608. DOI: 10.1016/j.bone.2020.115608. View

17.

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

18.

Pike J, Christakos S . Biology and Mechanisms of Action of the Vitamin D Hormone. Endocrinol Metab Clin North Am. 2017; 46(4):815-843. PMC: 5762112. DOI: 10.1016/j.ecl.2017.07.001. View

19.

Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J . Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2(12):e1917789. PMC: 6991219. DOI: 10.1001/jamanetworkopen.2019.17789. View

20.

Mohsenzade P, Amirhakimi A, Honar N, Saki F, Omrani G, Dabbaghmanesh M . Bone density, fractures and the associated factors in iranian children and adolescent with Osteogenesis Imperfecta. BMC Pediatr. 2021; 21(1):37. PMC: 7807702. DOI: 10.1186/s12887-020-02491-1. View